← LTP

LTPLTR PHARMA LIMITED

Announcement history available from 1 August 2025

Fromto
Date / TimeTitleTypeMSReport Codes
11 Aug 2026, 18:32SPONTAN Real-World Study Reports 93% ResponseCompany UpdateMS11001
28 July 2026, 19:01Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly ReportsMS19004, 19009
20 July 2026, 18:55LTR Executes U.S. Commercial Agreement with StriveCompany UpdateMS11001
17 July 2026, 18:48LTR Executes Definitive U.S. Commercial Agreement with ShedCompany UpdateMS11001
11 July 2026, 02:28Notification regarding unquoted securities - LTPOther—06021
24 June 2026, 18:22OROFLOW Clinical Study Receives Ethics ApprovalCompany Update—11001
16 June 2026, 00:16Response to ASX Aware LetterASX QueryMS17003
11 June 2026, 18:38LTR Secures Exclusive U.S. Pharmacy Partner for ROXUSCompany UpdateMS11001
9 June 2026, 18:35LTR Secures First U.S. Commercial Agreement for ROXUSCompany UpdateMS11001
1 May 2026, 19:19Investor PresentationPresentationsMS03026
1 May 2026, 19:18SPONTAN Phase II data show rapid onset, support FDA pathwayCompany UpdateMS09014, 11001
29 Apr 2026, 18:29Trading HaltTrading Halt / SuspensionMS09007
28 Apr 2026, 18:52Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly ReportsMS19003, 19008
11 Mar 2026, 19:40Investor PresentationPresentations—03026
5 Mar 2026, 19:31SPONTAN Phase II Clinical Study Completes RecruitmentCompany UpdateMS11001
26 Feb 2026, 19:12Appendix 4D and Half Yearly ReportFinancial ResultsMS03004, 03009, 03010, 03015, 03019
10 Feb 2026, 23:20Application for quotation of securities - LTPOther—06020
2 Feb 2026, 19:46SPONTAN Shows Positive Outcomes in Younger Men with EDCompany UpdateMS11001
28 Jan 2026, 19:27Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly ReportsMS19002, 19007
22 Jan 2026, 19:52First Patients Dosed in SPONTAN Phase II Clinical StudyCompany UpdateMS11001
22 Jan 2026, 02:35Application for quotation of securities - LTPOther—06020
17 Jan 2026, 03:58Notification regarding unquoted securities - LTPOther—06021
13 Jan 2026, 19:23Patient Recruitment Commences for SPONTAN Phase II StudyCompany Update—11001
8 Jan 2026, 20:14SPONTAN Phase 1 Study Accepted for WMSM 2026 PodiumCompany Update—11001
23 Dec 2025, 04:03Notification regarding unquoted securities - LTPOther—06021
17 Dec 2025, 20:12LTR Pharma Surpasses 1,000 SPONTAN PrescriptionsCompany Update—11001
11 Dec 2025, 20:45Application for quotation of securities - LTPOther—06020
10 Dec 2025, 20:38TGA Provides Regulatory Clearance for SPONTAN Phase IICompany UpdateMS11001
3 Dec 2025, 20:19Ethics Approval Received for SPONTAN Phase II Clinical StudyCompany UpdateMS11001
3 Dec 2025, 02:12Release of Restricted Securities from ASX Mandatory EscrowSecurities Administration—06009
21 Nov 2025, 02:43Change of Director's Interest Notice - M McGuireDirector Interests—02009
21 Nov 2025, 02:40Change of Director's Interest Notice - J ChickDirector Interests—02009
21 Nov 2025, 02:38Change of Director's Interest Notice - L RodneDirector Interests—02009
20 Nov 2025, 21:13Notification regarding unquoted securities - LTPOther—06021
20 Nov 2025, 21:06Notification regarding unquoted securities - LTPOther—06021
20 Nov 2025, 20:59Application for quotation of securities - LTPOther—06020
19 Nov 2025, 19:32Bell Potter Healthcare conference presentationPresentations—03026
30 Oct 2025, 20:43Investor PresentationPresentations—03026
29 Oct 2025, 19:51Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly ReportsMS19001, 19006
25 Oct 2025, 03:32Results of MeetingMeetings & Governance—08003
25 Oct 2025, 01:35AGM PresentationPresentations—03026, 15002
6 Oct 2025, 19:37LTR increases LevOmega stake to 43% with $1m investmentCompany UpdateMS11001
26 Sept 2025, 19:56Application for quotation of securities - LTPOther—06020
23 Sept 2025, 23:56Notice of Annual General Meeting/Proxy FormMeetings & Governance—08001, 08004, 16002
22 Sept 2025, 18:27LTR Pharma secures 33% ownership in LevOmega Pty LtdCompany UpdateMS11001
29 Aug 2025, 18:49FY25 Results AnnouncementFinancial ResultsMS03003
29 Aug 2025, 18:49Appendix 4G and Corporate Governance StatementCompany Administration—03024, 03025
29 Aug 2025, 18:48Appendix 4E and Annual Report to ShareholdersFinancial ResultsMS03001, 03002, 03003, 03011, 03012, 03013, 03020
25 Aug 2025, 19:04SPONTAN Case Series - Strong Post-Prostatectomy ResultsCompany UpdateMS11001
22 Aug 2025, 19:2318-Month Shelf Life Strengthens SPONTAN CommercialisationCompany UpdateMS11001
1–50 of 53
1 / 2